Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuther, U., Busies, S., 2010.

J Clin Oncol 28(Sup. abstr e15086). doi: 10.1200/jco.2010.28.15_suppl.e15086

Studie: TNK; Indikation: Nierenzellkarzinom; Jahr: 2010; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com